Related Experiment Video
Updated: Apr 11, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Minimal-change disease secondary to etanercept
Mariko Koya1, Raimund Pichler2, J Ashley Jefferson2
1Department of Internal Medicine , University of Washington , Seattle, WA , USA.
Abstract:
Etanercept is a soluble tumor necrosis factor alpha (TNFα) receptor which is widely used in the treatment of rheumatoid arthritis, psoriasis and other autoimmune inflammatory disorders. It is known for its relative lack of nephrotoxicity; however, there are reports on the development of nephrotic syndrome associated with the treatment with TNFα antagonists. Here, we describe a patient with psoriasis who developed biopsy-proven minimal-change disease (MCD) shortly after initiating etanercept. Our case is unique in that the MCD resolved after discontinuation of this medication, notably without the use of corticosteroids, strongly suggesting a drug-related phenomenon.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Nephrotic Syndrome I : Introduction